JUN and neoplasm: Conversely, Lynn at al. have shown that CAR T cells engineered to overexpress c-Jun are resistant to exhaustion, suggesting that the JNK/c-Jun pathway is a suitable target for immunotherapy-based combination approaches to reinvigorate anti-tumor immune functions [30].